Anti-SARS-CoV-2 Antibody-Containing Plasma Improves Outcome in Patients with Hematologic or Solid Cancer and Severe COVID-19: A Randomized Clinical Trial

Scientists performed a randomized, open-label, in hospitalized patients with severe COVID-19 (n = 134) within four risk groups, randomized to standard of care or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma.